Patents by Inventor Hilary Boucher

Hilary Boucher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factors controlling drug release in cross-linked poly(valerolactone) based matrices
    Patent number: 11905377
    Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 20, 2024
    Assignees: Pendant Biosciences, Inc., The Governing Council of the University of Toronto
    Inventors: Timothy Tordella Ruckh, Carl Eric Elmquist, David Michael Stevens, Frantz Le Dévédec, Hilary Boucher, Christine Allen
  • FACTORS CONTROLLING DRUG RELEASE IN CROSS-LINKED POLY(VALEROLACTONE) BASED MATRICES
    Publication number: 20200407514
    Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer.
    Type: Application
    Filed: January 17, 2020
    Publication date: December 31, 2020
    Inventors: Timothy Tordella Ruckh, Carl Eric Elmquist, David Michael Stevens, Frantz Le Dévédec, Hilary Boucher, Christine Allen